| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 376 0 |
| Căutarea după subiecte similare conform CZU |
| 616.98:578.834.1:614.1(612) (1) |
| Boli transmisibile. Boli infecţionase şi contagioase, stări febrile (587) |
| Virologie (446) |
| Populare. Depopulare (22) |
 SM ISO690:2012AQEEHAL, Hanan, ALARBI, Ahmed, MANEEA, Haytham, BENMANSUR, Mahmud, ELTURKI, Abdelhadi, ZAABIA, Anud, BENTOUTA, Rachid, GEBRIL, Jebril. Retrospective study on the prevalence of COVID-19 confirmed cases and evidence of gender bias in Libya. In: One Health and Risk Management, 2022, nr. 3(1), pp. 29-37. ISSN 2587-3458. DOI: https://doi.org/10.38045/ohrm.2022.1.01 |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| One Health and Risk Management | ||||||
| Numărul 3(1) / 2022 / ISSN 2587-3458 /ISSNe 2587-3466 | ||||||
|
||||||
| DOI:https://doi.org/10.38045/ohrm.2022.1.01 | ||||||
| CZU: 616.98:578.834.1:614.1(612) | ||||||
| Pag. 29-37 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Introduction. To stop SARS-CoV-2 from spreading, it's crucial to have a solid understanding of the baseline characteristics of demographic variables, clinical symptoms, and comorbidity so that quarantining and testing protocols can be developed. Material and methods. A ret-rospective study was conducted on COVID-19 Laboratory confirmed cases. Data were col-lected by using kobo toolbox, demographic variables, clinical symptoms, and Comorbidity was considered. Yates-corrected chi2 tests and Multinomial Logistic Regression was used to esti-mate the odds ratio (OR) and 95% confidence interval (CI) of factors and their impact on COVID-19 prevalence. Results. A total of 6302 of which 3536(56.1%) men and 2766 (44%) women with a mean age (±SD) of 44±17.6 years were included within the study. Clinical symp-toms and Comorbidity were significant for both sexes p<0.0001. Multinomial Logistic Regres-sion confirmed that age <55, 3 or more symptoms (OR=1.130 CI95% 1.013-1.261) and 3 or more comorbidities (OR=1.035 Cl95% 0.942-1.137) were a significant risk factor for COVID-19 prevalence in male patients, among women, age 85>/=, 3 or more symptoms (p<0.0001, OR=1.995 CI95% 1.335-2.992) and 3 or more comorbidities (p<0.0001, OR=1.538 Cl95% 1.045-2.640) were significant risk factor for COVID-19 prevalence in females. Conclusions. Our study suggests that the prevalence of COVID-19 patients and symptoms was higher in men than women. The high prevalence of smoking could have contributed to the high prevalence of COVID-19 among men. Study also suggests that the presence of at least one or combined comorbidities are risk factors of COVID-19 prevalence and a potential risk factor COVID-19 - related outcomes. More efforts should be exercised to protect patients with one or more comorbidities from being exposed to infection. |
||||||
| Cuvinte-cheie SARS-CoV-2, comorbidity, clinical symptoms, Libya, SARS-CoV-2, comor-biditate, simptome clinice, Libia |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-147252</cfResPublId> <cfResPublDate>2022-01-05</cfResPublDate> <cfVol>1</cfVol> <cfIssue>3</cfIssue> <cfStartPage>29</cfStartPage> <cfISSN>2587-3458</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/147252</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Retrospective study on the prevalence of COVID-19 confirmed cases and evidence of gender bias in Libya</cfTitle> <cfKeyw cfLangCode='EN' cfTrans='o'>SARS-CoV-2; comorbidity; clinical symptoms; Libya; SARS-CoV-2; comor-biditate; simptome clinice; Libia</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Introduction. To stop SARS-CoV-2 from spreading, it's crucial to have a solid understanding of the baseline characteristics of demographic variables, clinical symptoms, and comorbidity so that quarantining and testing protocols can be developed. Material and methods. A ret-rospective study was conducted on COVID-19 Laboratory confirmed cases. Data were col-lected by using kobo toolbox, demographic variables, clinical symptoms, and Comorbidity was considered. Yates-corrected chi2 tests and Multinomial Logistic Regression was used to esti-mate the odds ratio (OR) and 95% confidence interval (CI) of factors and their impact on COVID-19 prevalence. Results. A total of 6302 of which 3536(56.1%) men and 2766 (44%) women with a mean age (±SD) of 44±17.6 years were included within the study. Clinical symp-toms and Comorbidity were significant for both sexes p<0.0001. Multinomial Logistic Regres-sion confirmed that age <55, 3 or more symptoms (OR=1.130 CI95% 1.013-1.261) and 3 or more comorbidities (OR=1.035 Cl95% 0.942-1.137) were a significant risk factor for COVID-19 prevalence in male patients, among women, age 85>/=, 3 or more symptoms (p<0.0001, OR=1.995 CI95% 1.335-2.992) and 3 or more comorbidities (p<0.0001, OR=1.538 Cl95% 1.045-2.640) were significant risk factor for COVID-19 prevalence in females. Conclusions. Our study suggests that the prevalence of COVID-19 patients and symptoms was higher in men than women. The high prevalence of smoking could have contributed to the high prevalence of COVID-19 among men. Study also suggests that the presence of at least one or combined comorbidities are risk factors of COVID-19 prevalence and a potential risk factor COVID-19 - related outcomes. More efforts should be exercised to protect patients with one or more comorbidities from being exposed to infection.</p></cfAbstr> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Introducere. Pentru a stopa răspândirea SARS-CoV-2, este esențial să fie bine înțelese carac-teristicile de bază ale variabilelor demografice, simptomele clinice și comorbiditatea, astfel încât să poată fi dezvoltate protocoale de carantină și de testare. Material și metode. A fost efectuat un studiu retrospectiv pe cazurile confirmate de laboratorul COVID-19. S-au colectat date prin aplicarea Kobo toolbox, luându-se în considerare variabilele demografice, simp-tomele clinice și comorbiditatea. Pentru a estima riscul relativ (OR), intervalul de încredere de 95% (CI) al factorilor și impactul acestora asupra prevalenței COVID-19, au fost utilizate Yates corecția pentru testele chi pătrat și regresia logistică multinominală. Rezultate. În stu-diu au fost incluse 6302 persoane, dintre care 3536 (56,1%) bărbați și 2766 (44%) femei, cu vârsta medie (±SD) de 44±17,6 ani. Simptomele clinice și comorbiditatea au fost semnificative pentru ambele sexe p<0,0001. Regresia logistică multinominală a confirmat că vârsta <55, 3, mai multe simptome (OR=1,130 CI95% 1,013-1,261), 3 sau mai multe comorbidități (OR=1,035 CL95% 0,942-1,137) au constituit un factor de risc semnificativ pentru prevalența COVID-19 la bărbați, iar în rândul femeilor, vârsta de 85 de ani >/=, 3 sau mai multe simptome (p<0,0001, OR=1,995 CI95% 1,35-2,992), 3 sau mai multe comorbidități (p<0,0001 OR=1,538 CL95% 1,045-2,640) au prezentat factori de risc semnificativ pentru incidența COVID-19. Concluzii. Studiul constată că prevalența pacienților și a simptomelor COVID-19 a fost mai mare la bărbați decât la femei. Nivelul ridicat al fumatului ar fi putut contribui la incidența înaltă de COVID-19 în rândul bărbaților. Cercetarea noastră sugerează, de asemenea, că prezența a cel puțin uneia dintre comorbidități sau a unor comorbidităților combinate sporește riscul incidenței COVID-19 și se prezintă ca un potențial factor de risc COVID-19 – rezultatele fiind asociate. Ar trebui să se depună mai multe eforturi în scopul protejării pa-cienților cu una sau cu mai multe comorbidități de expunerea la infecții.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-95822</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-95823</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-95824</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-95825</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-95826</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-95827</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-95828</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-95829</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> </cfPers_ResPubl> <cfFedId> <cfFedIdId>ibn-doi-147252</cfFedIdId> <cfFedId>10.38045/ohrm.2022.1.01</cfFedId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFedId_Class> <cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId> <cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId> </cfFedId_Class> <cfFedId_Srv> <cfSrvId>5123451</cfSrvId> <cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId> </cfFedId_Srv> </cfFedId> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-95822</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95822-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Aqeehal</cfFamilyNames> <cfFirstNames>Hanan</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-95823</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95823-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Alarbi</cfFamilyNames> <cfFirstNames>Ahmed</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-95824</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95824-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Maneea</cfFamilyNames> <cfFirstNames>Haytham</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-95825</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95825-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Benmansur</cfFamilyNames> <cfFirstNames>Mahmud</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-95826</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95826-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Elturki</cfFamilyNames> <cfFirstNames>Abdelhadi</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-95827</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95827-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Zaabia</cfFamilyNames> <cfFirstNames>Anud</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-95828</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95828-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Bentouta</cfFamilyNames> <cfFirstNames>Rachid</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-95829</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-95829-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2022-01-05T24:00:00</cfStartDate> <cfFamilyNames>Gebril</cfFamilyNames> <cfFirstNames>Jebril</cfFirstNames> </cfPersName_Pers> </cfPers> <cfSrv> <cfSrvId>5123451</cfSrvId> <cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName> <cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr> <cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw> </cfSrv> </CERIF>
|
|
|
